[Skip navigation]FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
 
Powered by Google
 

Drug Approvals for January 2001

line

Definitions and Notes

Original New Drug Applications


Original Application #: 021208
Approval Date: 12-JAN-01
Trade Name: REMERON SOLTAB
Chemical Type: 3
Therapeutic Potential: S
Dosage Form: TABLET, ORALLY DISINTEGRATING
Applicant: ORGANON INC
Active Ingredient(s): MIRTAZAPINE
OTC/RX Status: RX
Indication(s): For the treatment of depression



Original Application #: 021252
Approval Date: 05-JAN-01
Trade Name: CANASA
Chemical Type: 5
Therapeutic Potential: P
Dosage Form: SUPPOSITORY
Applicant: AXCAN SCANDIPHARM INC
Active Ingredient(s): MESALAMINE
OTC/RX Status: RX
Indication(s): Treatment of active ulcerative proctitis

Efficacy Supplemental New Drug Applications


Application #: 020560 Efficacy Supplement #: 025
Type: SE2 to Original New Drug Application
Approval Date: 31-JAN-01
Trade Name: FOSAMAX
Dosage Form: TABLET
Applicant: MERCK AND CO INC
Active Ingredient(s): ALENDRONATE SODIUM
OTC/RX Status: RX
Efficacy Claim: For the treatment to increase bone mass in men with osteoporosis


Approvable Original New Drug Applications

 


Original Abbreviated New Drug Applications


Original Abbreviated Application # 075887
Approval Date: 05-JAN-01
Trade Name: FLUVOXAMINE MALEATE
Dosage Form: TABLET
Applicant: INVAMED INC
Active Ingredient(s): FLUVOXAMINE MALEATE
OTC/RX Status: RX



Original Abbreviated Antibiotic Application# 065057
Approval Date: 05-JAN-01
Trade Name: CEFACLOR
Dosage Form: TABLET, EXTENDED RELEASE
Applicant: ZENITH GOLDLINE PHARMACEUTICALS
Active Ingredient(s): CEFACLOR
OTC/RX Status: RX


Original Abbreviated and 505(b)(2) New Drug Applications with Tentative Approval


Original Abbreviated Application #: 075790
Tentative Approval Date: 01-JAN-01
Trade Name: LORATADINE
Dosage Form: TABLET
Applicant: MYLAN PHARMACEUTICALS INC
Active Ingredient(s): LORATADINE
OTC/RX Status: RX


Labeling Supplements to Original New Drug Applications


Application #: 020560 Labeling Supplement#: 024
To Original New Drug Application
Approval Date: 31-JAN-01
Trade Name: FOSAMAX
Dosage Form: TABLET
Applicant: MERCK AND CO INC
Active Ingredient(s): ALENDRONATE SODIUM
OTC/RX Status: RX



Application #: 019297 Labeling Supplement#: 022
To Original New Drug Application
Approval Date: 31-JAN-01
Trade Name: NOVANTRONE
Dosage Form: INJECTABLE
Applicant: IMMUNEX CORP
Active Ingredient(s): MITOXANTRONE HYDROCHLORIDE
OTC/RX Status: RX



Application #: 016979 Labeling Supplement#: 049
To Original New Drug Application
Approval Date: 31-JAN-01
Trade Name: MEGACE
Dosage Form: TABLET
Applicant: BRISTOL MYERS SQUIBB
Active Ingredient(s): MEGESTROL ACETATE
OTC/RX Status: RX



Application #: 021251 Labeling Supplement#: 001
To Original New Drug Application
Approval Date: 30-JAN-01
Trade Name: KALETRA
Dosage Form: SOLUTION
Applicant: ABBOTT LABORATORIES
Active Ingredient(s): LOPINAVIR; RITONAVIR
OTC/RX Status: RX



Application #: 021226 Labeling Supplement#: 001
To Original New Drug Application
Approval Date: 30-JAN-01
Trade Name: KALETRA
Dosage Form: CAPSULE
Applicant: ABBOTT LABORATORIES
Active Ingredient(s): LOPINAVIR; RITONAVIR
OTC/RX Status: RX



Application #: 020180 Labeling Supplement#: 022
To Original New Drug Application
Approval Date: 30-JAN-01
Trade Name: PROSCAR
Dosage Form: TABLET
Applicant: MERCK AND CO INC
Active Ingredient(s): FINASTERIDE
OTC/RX Status: RX



Application #: 012142 Labeling Supplement#: 103
To Original New Drug Application
Approval Date: 30-JAN-01
Trade Name: CYTOXAN
Dosage Form: INJECTABLE
Applicant: BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
Active Ingredient(s): CYCLOPHOSPHAMIDE
OTC/RX Status: RX



Application #: 012141 Labeling Supplement#: 086
To Original New Drug Application
Approval Date: 30-JAN-01
Trade Name: CYTOXAN
Dosage Form: TABLET
Applicant: BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
Active Ingredient(s): CYCLOPHOSPHAMIDE
OTC/RX Status: RX



Application #: 020985 Labeling Supplement#: 001
To Original New Drug Application
Approval Date: 29-JAN-01
Trade Name: CARAC
Dosage Form: EMULSION, CREAM
Applicant: DERMIK LABORATORIES INC
Active Ingredient(s): FLUOROURACIL
OTC/RX Status: RX



Application #: 020152 Labeling Supplement#: 025
To Original New Drug Application
Approval Date: 23-JAN-01
Trade Name: SERZONE
Dosage Form: TABLET
Applicant: BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
Active Ingredient(s): NEFAZODONE HYDROCHLORIDE
OTC/RX Status: RX



Application #: 020180 Labeling Supplement#: 019
To Original New Drug Application
Approval Date: 17-JAN-01
Trade Name: PROSCAR
Dosage Form: TABLET
Applicant: MERCK RESEACH LABORATORIES
Active Ingredient(s): FINASTERIDE
OTC/RX Status: RX



Application #: 019653 Labeling Supplement#: 027
To Original New Drug Application
Approval Date: 16-JAN-01
Trade Name: ORTHO CYCLEN-28
Dosage Form: TABLET
Applicant: R.W. JOHNSON PHARMACEUTICAL AND RESEARCH INSTITUTE
Active Ingredient(s): NORGESTIMATE/ETHINYL ESTRADIOL
OTC/RX Status: RX



Application #: 019697 Labeling Supplement#: 024
To Original New Drug Application
Approval Date: 16-JAN-01
Trade Name: ORTHO TRI-CYCLEN
Dosage Form: TABLET
Applicant: R.W. JOHNSON PHARMACEUTICAL AND RESEARCH INSTITUTE
Active Ingredient(s): NORGESTIMATE/ETHINY ESTRADIOL
OTC/RX Status: RX



Application #:019821 Labeling Supplement#: 004
To Original New Drug Application
Approval Date: 11-JAN-01
Trade Name: SORIATANE
Dosage Form: CAPSULE
Applicant: HOFFMAN LA ROCHE INC
Active Ingredient(s): ACTRETIN
OTC/RX Status: RX



Application #: 021025 Labeling Supplement#: 003
To Original New Drug Application
Approval Date: 05-JAN-01
Trade Name: EXELON
Dosage Form: SOLUTION
Applicant: NOVARTIS PHARMACEUTICALS CORP
Active Ingredient(s): RIVASTIGMINE TARTRATE
OTC/RX Status: RX



Application #: 020823 Labeling Supplement#: 003
To Original New Drug Application
Approval Date: 05-JAN-01
Trade Name: EXELON
Dosage Form: CAPSULE
Applicant: NOVARTIS PHARMACEUTICALS CORP
Active Ingredient(s): RIVASTIGMINE TARTRATE
OTC/RX Status: RX



Application #: 020596 Labeling Supplement#: 012
To Original New Drug Application
Approval Date: 05-JAN-01
Trade Name: EPIVIR
Dosage Form: SOLUTION
Applicant: GLAXO WELLCOME INC
Active Ingredient(s): LAMIVUDINE
OTC/RX Status: RX



Application #: 020564 Labeling Supplement#: 011
To Original New Drug Application
Approval Date: 05-JAN-01
Trade Name: EPIVIR
Dosage Form: TABLET
Applicant: GLAXO WELLCOME INC
Active Ingredient(s): LAMIVUDINE
OTC/RX Status: RX



Application #: 050742 Labeling Supplement#: 005
To Original New Drug Application
Approval Date: 04-JAN-01
Trade Name: STROMECTOL
Dosage Form: TABLET
Applicant: MERCK RESEARCH LABORATORIES DIV MERCK CO INC
Active Ingredient(s): IVERMECTIN
OTC/RX Status: RX



Application #: 050742 Labeling Supplement#: 002
To Original New Drug Application
Approval Date: 04-JAN-01
Trade Name: STROMECTOL
Dosage Form: TABLET
Applicant: MERCK RESEARCH LABORATORIES DIV MERCK CO INC
Active Ingredient(s): IVERMECTIN
OTC/RX Status: RX

 

 

Back to Top     Back to Drug Approvals List

 

Date created: March 08, 2001; last updated: June 20, 2005

horizonal rule